COMMUNIQUÉS West-GlobeNewswire
-
The MUCH Foundation’s Raise Craze raises $115,765 for breast cancer care at the MUHC
17/11/2026 -
La campagne Raise Craze de la Fondation du CUSM recueille 115 765 $ pour les soins contre le cancer du sein au CUSM
17/11/2026 -
Daxor Expands Midwest Footprint with Launch of ezBVA Lab Program at Premier Kansas Academic Medical Center
17/11/2026 -
Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering
17/11/2026 -
BetterLife Pharma Announces Stock Option Grant
17/11/2026 -
MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain
17/11/2026 -
Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion
17/11/2026 -
Senti Bio Announces Reverse Stock Split
17/11/2026 -
Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion Accelerates
17/11/2026 -
Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update
17/11/2026 -
Nine-month interim report (Q3) 2026 (unaudited)
17/11/2026 -
Davion Healthcare Plc Provides Shareholders with Guidance on Direct Registration and Confirmation of Share Ownership
17/11/2026 -
Weight Watchers Announces Discounted Prepayment Solicitation to Utilize Up to $10 Million to Reduce Term Loan Debt
17/11/2026 -
Acoramidis Was Associated with Lower Risk of Worsening Heart Failure Versus Tafamidis in Real-World Study and Reduced Heart Failure Events Within One Month in ATTRibute-CM
17/11/2026 -
Noom Launches OpenRx, a New Peptide and Preventive Health Brand
17/11/2026 -
Hyalex Orthopaedics Announces First Commercial Case with the Slalom MTP Implant for Hallux Rigidus
17/11/2026 -
Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026
17/11/2026 -
Cognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study
17/11/2026 -
Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer
17/11/2026
Pages